全文获取类型
收费全文 | 50083篇 |
免费 | 5213篇 |
国内免费 | 114篇 |
专业分类
耳鼻咽喉 | 464篇 |
儿科学 | 1257篇 |
妇产科学 | 1157篇 |
基础医学 | 7459篇 |
口腔科学 | 1117篇 |
临床医学 | 6193篇 |
内科学 | 9329篇 |
皮肤病学 | 587篇 |
神经病学 | 4930篇 |
特种医学 | 1901篇 |
外国民族医学 | 57篇 |
外科学 | 6466篇 |
综合类 | 1049篇 |
一般理论 | 45篇 |
预防医学 | 5522篇 |
眼科学 | 1205篇 |
药学 | 3818篇 |
中国医学 | 34篇 |
肿瘤学 | 2820篇 |
出版年
2021年 | 771篇 |
2020年 | 482篇 |
2019年 | 759篇 |
2018年 | 842篇 |
2017年 | 638篇 |
2016年 | 707篇 |
2015年 | 766篇 |
2014年 | 1120篇 |
2013年 | 1734篇 |
2012年 | 2387篇 |
2011年 | 2429篇 |
2010年 | 1430篇 |
2009年 | 1250篇 |
2008年 | 2257篇 |
2007年 | 2236篇 |
2006年 | 2279篇 |
2005年 | 2224篇 |
2004年 | 2224篇 |
2003年 | 1952篇 |
2002年 | 1915篇 |
2001年 | 1550篇 |
2000年 | 1667篇 |
1999年 | 1405篇 |
1998年 | 615篇 |
1997年 | 528篇 |
1996年 | 422篇 |
1995年 | 500篇 |
1994年 | 447篇 |
1993年 | 406篇 |
1992年 | 1089篇 |
1991年 | 1130篇 |
1990年 | 1040篇 |
1989年 | 1026篇 |
1988年 | 1024篇 |
1987年 | 888篇 |
1986年 | 884篇 |
1985年 | 851篇 |
1984年 | 710篇 |
1983年 | 593篇 |
1982年 | 387篇 |
1981年 | 360篇 |
1980年 | 346篇 |
1979年 | 672篇 |
1978年 | 521篇 |
1977年 | 443篇 |
1976年 | 412篇 |
1975年 | 387篇 |
1974年 | 446篇 |
1973年 | 449篇 |
1972年 | 388篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Heather L. Brown 《Journal of emergency nursing》2021,47(2):321-325
The coronavirus 2019 pandemic has affected almost every aspect of health care delivery in the United States, and the emergency medicine system has been hit particularly hard while dealing with this public health crisis. In an unprecedented time in our history, medical systems and clinicians have been asked to be creative, flexible, and innovative, all while continuing to uphold the important standards in the US health care system. To continue providing quality services to patients during this extraordinary time, care providers, organizations, administrators, and insurers have needed to alter longstanding models and procedures to respond to the dynamics of a pandemic. The Emergency Medicine Treatment and Active Labor Act of 1986, or EMTALA, is 1 example of where these alterations have allowed health care facilities and clinicians to continue their work of caring for patients while protecting both the patients and the clinicians themselves from infectious exposures at the same time. 相似文献
2.
3.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献4.
5.
6.
7.
8.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
9.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
10.
Josh Greenstein Devjani Das Josie Acuna Monica Kapoor Cara Brown Abbas Husain Brendan Lally Barry Hahn 《The American journal of emergency medicine》2019,37(2):313-316